

Chien-Hung Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6652733/publications.pdf>

Version: 2024-02-01

103
papers

2,429
citations

201385

27
h-index

233125

45
g-index

108
all docs

108
docs citations

108
times ranked

2484
citing authors

#	ARTICLE	IF	CITATIONS
1	Correlation between ultrasonographic and pathologic diagnoses of hepatitis B and C virus-related cirrhosis. <i>Journal of Gastroenterology</i> , 2003, 38, 153-157.	2.3	179
2	The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. <i>Journal of Hepatology</i> , 2014, 61, 515-522.	1.8	136
3	High-resolution copy number variation analysis of schizophrenia in Japan. <i>Molecular Psychiatry</i> , 2017, 22, 430-440.	4.1	104
4	Clinical Significance of Hepatitis B Virus (HBV) Genotypes and Precore and Core Promoter Mutations Affecting HBV e Antigen Expression in Taiwan. <i>Journal of Clinical Microbiology</i> , 2005, 43, 6000-6006.	1.8	94
5	Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 381-403.	0.8	92
6	Modelling NAFLD disease burden in four Asian regions—2019–2030. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 801-811.	1.9	92
7	Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1984-1992.e1.	2.4	84
8	Prevalence and Clinical Implications of Hepatitis B Virus Genotypes in Southern Taiwan. <i>Scandinavian Journal of Gastroenterology</i> , 2003, 38, 95-101.	0.6	76
9	Taiwan consensus statement on the management of chronic hepatitis B. <i>Journal of the Formosan Medical Association</i> , 2019, 118, 7-38.	0.8	64
10	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
11	Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1213-1218.	0.8	60
12	Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 218-228.	1.9	55
13	Probability of HBsAg loss after nucleos(t)ide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	1.8	54
14	Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. <i>Clinical Microbiology and Infection</i> , 2018, 24, 997-1003.	2.8	49
15	A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1017-1024.	2.4	48
16	Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. <i>Journal of Hepatology</i> , 2014, 60, 1127-1134.	1.8	45
17	Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy after biochemical breakthrough of YMDD mutants. <i>Journal of Hepatology</i> , 2004, 41, 454-461.	1.8	42
18	The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 590-597.	1.0	42

#	ARTICLE	IF	CITATIONS
19	Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. <i>Oncotarget</i> , 2017, 8, 92431-92441.	0.8	41
20	Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. <i>Journal of Viral Hepatitis</i> , 2017, 24, 599-607.	1.0	40
21	Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. <i>Journal of Hepatology</i> , 2006, 44, 76-82.	1.8	39
22	The effects of total contact insole with forefoot medial posting on rearfoot movement and foot pressure distributions in patients with flexible flatfoot. <i>Clinical Neurology and Neurosurgery</i> , 2015, 129, S8-S11.	0.6	39
23	Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2154-2163.	1.3	37
24	Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy. <i>Liver International</i> , 2016, 36, 1793-1799.	1.9	34
25	Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study. <i>Clinical Microbiology and Infection</i> , 2017, 23, 464-469.	2.8	32
26	The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. <i>Journal of Infectious Diseases</i> , 2019, 219, 1624-1633.	1.9	32
27	The Changes of Liver Stiffness and Its Associated Factors for Chronic Hepatitis B Patients with Entecavir Therapy. <i>PLoS ONE</i> , 2014, 9, e93160.	1.1	30
28	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	1.9	29
29	Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2803-2812.e2.	2.4	28
30	Febuxostat-associated drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 689-692.	0.7	27
31	Arthroscopic posterior cruciate ligament reconstruction with quadriceps tendon-patellar bone autograft. <i>Archives of Orthopaedic and Trauma Surgery</i> , 1999, 119, 86-88.	1.3	26
32	Three-year efficacy and safety of tenofovir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1307-1314.	1.4	25
33	Tenofovir versus Entecavir in Treatment of Chronic Hepatitis B Virus with Severe Acute Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3168-3173.	1.4	24
34	Comparison of prevalence for paraumbilical vein patency in patients with viral and alcoholic liver cirrhosis. <i>American Journal of Gastroenterology</i> , 2002, 97, 2415-2418.	0.2	23
35	Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2989-2997.e3.	2.4	23
36	A Comparative Assessment of Implant Site Viability in Humans and Rats. <i>Journal of Dental Research</i> , 2018, 97, 451-459.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. <i>PLoS ONE</i> , 2019, 14, e0222221.	1.1	19
38	Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. <i>Hepatology International</i> , 2020, 14, 317-325.	1.9	19
39	A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. <i>Hepatology International</i> , 2013, 7, 832-843.	1.9	18
40	Simultaneous anterior dislocation of the shoulder and fracture of the ipsilateral humeral shaft. <i>International Orthopaedics</i> , 1998, 22, 65-67.	0.9	17
41	Clinical Impact of Gadoteric Acid-Enhanced Magnetic Resonance Imaging on Hepatoma Management: A Prospective Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1197-1205.	1.1	17
42	Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. <i>Hepatology International</i> , 2021, 15, 301-309.	1.9	17
43	Diabetes mellitus is associated with gastroesophageal variceal bleeding in cirrhotic patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2014, 30, 515-520.	0.8	16
44	Liver resection of hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guideline recommendations: Results from a high-volume liver surgery center in East Asia. <i>Journal of Surgical Oncology</i> , 2020, 122, 1587-1594.	0.8	16
45	Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection. <i>Liver Cancer</i> , 2022, 11, 22-37.	4.2	16
46	Impact of Steatosis on Long-Term Histological Outcome in Chronic Hepatitis C after Antiviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 483-489.	0.6	16
47	The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2019, 14, e0214323.	1.1	14
48	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	2.4	14
49	Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1695-1706.	1.9	14
50	Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon- α in hepatitis B antigen-positive patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 461-468.	1.4	13
51	A combination of the on-treatment γ -GluT and alpha-fetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir. <i>Liver International</i> , 2018, 38, 1997-2005.	1.9	13
52	Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation. <i>PLoS ONE</i> , 2020, 15, e0242113.	1.1	13
53	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	1.8	13
54	Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 833-840.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. <i>Digestive Diseases and Sciences</i> , 2020, 65, 1512-1519.	1.1	12
56	The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1141-1149.	1.0	12
57	Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants. <i>Antiviral Therapy</i> , 2012, 17, 701-709.	0.6	11
58	The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. <i>Liver International</i> , 2018, 38, 1064-1073.	1.9	11
59	Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 442-449.	1.4	11
60	The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. <i>Investigational New Drugs</i> , 2020, 38, 202-210.	1.2	11
61	On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1177.	1.7	11
62	Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience. <i>Liver International</i> , 2011, 31, 206-214.	1.9	9
63	Survival without peripheral neuropathy after massive acute arsenic poisoning: Treated by 2,3-dimercaptopropane-1-sulphonate. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2017, 42, 506-508.	0.7	9
64	Incidence and predictors of hepatocellular carcinoma beyond year 5 of entecavir therapy in chronic hepatitis B patients. <i>Hepatology International</i> , 2020, 14, 513-520.	1.9	9
65	Lamivudine treatment for recurrent pancreatitis associated with reactivation of chronic B hepatitis. <i>Digestive Diseases and Sciences</i> , 2002, 47, 564-567.	1.1	8
66	The effect of systemic antibiotic prophylaxis for cirrhotic patients with peptic ulcer bleeding after endoscopic interventions. <i>Hepatology International</i> , 2013, 7, 257-267.	1.9	8
67	Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis. <i>Scientific Reports</i> , 2019, 9, 7086.	1.6	8
68	Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan. <i>Journal of Viral Hepatitis</i> , 2020, 27, 866-872.	1.0	8
69	Earlier and Higher Rate of Hepatitis B Virus Relapse After Discontinuing Tenofovir Versus Entecavir in Hepatitis B e Antigen-Positive Patients. <i>Journal of Infectious Diseases</i> , 2022, 225, 1974-1981.	1.9	8
70	Peripheral blood toll-like receptor 4 correlates with rapid virological response to pegylated-interferon and ribavirin therapy in hepatitis C genotype 1 patients. <i>BMC Gastroenterology</i> , 2016, 16, 73.	0.8	7
71	MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. <i>Scientific Reports</i> , 2016, 6, 33816.	1.6	7
72	Correlations between hepatitis B virus genotype and cirrhotic or non-cirrhotic hepatoma. <i>Hepato-Gastroenterology</i> , 2004, 51, 552-5.	0.5	7

#	ARTICLE	IF	CITATIONS
73	Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion. <i>Hepatology International</i> , 2013, 7, 477-488.	1.9	6
74	A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir. <i>Hepatology International</i> , 2021, 15, 310-317.	1.9	6
75	Cementless Roy-Camille femoral component. <i>Archives of Orthopaedic and Trauma Surgery</i> , 1998, 118, 85-88.	1.3	4
76	Incorporating albumin-bilirubin grade and up-to-seven criteria to predict outcomes of patients with intermediate stage hepatocellular carcinoma after transarterial (chemo)embolization. <i>Journal of the Formosan Medical Association</i> , 2021, , .	0.8	4
77	Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. <i>Leukemia and Lymphoma</i> , 2021, 62, 2899-2906.	0.6	4
78	Predictors of In-Hospital Mortality for School-Aged Children with Severe Traumatic Brain Injury. <i>Brain Sciences</i> , 2021, 11, 136.	1.1	4
79	Expression of 14-3-3 sigma, cyclin-dependent kinases 2 and 4, p16, and Epstein-Barr nuclear antigen 1 in nasopharyngeal carcinoma. <i>Journal of Laryngology and Otolaryngology</i> , 2014, 128, 134-141.	0.4	3
80	Simplified Tai Chi 6-Form Apparatus for Balance in Elderly People with Alzheimer's Disease. <i>Journal of Medical and Biological Engineering</i> , 2019, 39, 682-692.	1.0	3
81	Hepatic Clostridium Perfringens Abscess Formation after Radiofrequency Ablation Therapy for Hepatocellular Carcinoma: Report of a Rare Case. <i>Case Reports in Oncology</i> , 2021, 14, 906-911.	0.3	3
82	Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study. <i>American Journal of Cancer Research</i> , 2020, 10, 3882-3895.	1.4	3
83	Predictors of In-Hospital Mortality for Road Traffic Accident-Related Severe Traumatic Brain Injury. <i>Journal of Personalized Medicine</i> , 2021, 11, 1339.	1.1	3
84	Real-world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects. <i>Journal of Viral Hepatitis</i> , 2020, 27, 505-513.	1.0	2
85	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	0.8	2
86	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	1.5	2
87	Muscle activation features of the osteoarthritic knee with patellar lateral subluxation. <i>Clinical Neurology and Neurosurgery</i> , 2015, 129, S30-S35.	0.6	1
88	The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan. <i>Biomedical Journal</i> , 2020, , .	1.4	1
89	Can the addition of ultrasound-guided genicular nerve block using 5% dextrose water augment the effect of autologous platelet rich plasma in treating elderly patients with knee osteoarthritis?. <i>Biomedical Journal</i> , 2020, , .	1.4	1
90	Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 621-628.	0.8	1

#	ARTICLE	IF	CITATIONS
91	Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3402-3411.	1.1	1
92	Keystone to Secure Safety After Stopping Nucleos(t)ide Analogue Therapy in Chronic Hepatitis B Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1890-1891.	2.4	1
93	Editorial: hepatitis B reactivation in patients with chronic hepatitis C treated with direct-acting antivirals – incidence, severity of hepatitis and lessons to learn. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1373-1374.	1.9	1
94	The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir. <i>Viruses</i> , 2022, 14, 362.	1.5	1
95	Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. <i>Viruses</i> , 2022, 14, 1189.	1.5	1
96	Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients – author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1106-1107.	1.9	0
97	Revisiting the accuracy of splenomegaly by sonography in patients with chronic hepatitis B. <i>Advances in Digestive Medicine</i> , 2020, 7, 30-35.	0.1	0
98	Editorial: increasing burden of nonalcoholic fatty liver disease – a call to action. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1430-1432.	1.9	0
99	On-treatment predictors of hepatocellular carcinoma in patients with chronic hepatitis B. <i>Liver International</i> , 2021, 41, 1700-1701.	1.9	0
100	IDDF2021-ABS-0078 – Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD)., 2021, .		0
101	High Titers of Hepatitis B Surface Antibodies Indicating Low Risk of Hepatitis B Virus-Related Hepatitis in Lymphoma Patients Treated with Rituximab-Based Chemotherapy. <i>Blood</i> , 2015, 126, 3869-3869.	0.6	0
102	The Change in Body Positioning to Improve Safety in Performing Ultrasound-Guided Supraclavicular Brachial Plexus Nerve Block. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021, 100, e60-e61.	0.7	0
103	The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays. <i>Virology Journal</i> , 2022, 19, 59.	1.4	0